Author(s):
Vipul Kumar, Sudhakar Kancharla, Manoj Kumar Jena
Email(s):
manoj.20283@lpu.co.in
DOI:
10.52711/0974-360X.2021.00699 
Address:
Vipul Kumar1, Sudhakar Kancharla2, Manoj Kumar Jena3*
1Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Punjab, India.
2Devansh Lab Werks, 234 Aquarius Drive, Homewood, Alabama, USA 35209.
3Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Punjab, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 8,
Year - 2021
ABSTRACT:
Since the outbreak of severe acute respiratory syndrome corona Virus -2 (SARS-CoV-2) has happened in December 2019 in Wuhan, China, the cases of novel coronavirus disease (COVID-19) is rapidly increasing worldwide. In the absence of specific drugs against COVID-19, the fast and reliable choice would be repurposing of existing drugs. Here, we have chosen one of the crucial enzymes of the SARS-CoV-2, Papain like protease (PLpro) and its mutant C111S for the structure-based in-silico screening of the FDA approved drugs. Firstly, the alignment of the wild type and mutant PLpro was done, and no significant change in the global structure was observed. Then based on the docking study, we have reported the best 3 compounds against a mutant and wild type PLpro. These lead compounds include amikacin and mafenide, which are well-known antibiotics. The binding affinity, as well as number of polar and non-polar interactions, indicates their potential against the PLpro. This computational study strongly suggests the experimental validations of the predicted compounds for a confident claim.
Cite this article:
Vipul Kumar, Sudhakar Kancharla, Manoj Kumar Jena. In silico screening of FDA approved drugs predicts the therapeutic potentials of Antibiotic drugs against the papain like protease of SARS-CoV-2. Research Journal of Pharmacy and Technology. 2021; 14(8):4035-9. doi: 10.52711/0974-360X.2021.00699
Cite(Electronic):
Vipul Kumar, Sudhakar Kancharla, Manoj Kumar Jena. In silico screening of FDA approved drugs predicts the therapeutic potentials of Antibiotic drugs against the papain like protease of SARS-CoV-2. Research Journal of Pharmacy and Technology. 2021; 14(8):4035-9. doi: 10.52711/0974-360X.2021.00699 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-8-5
REFERENCES:
1. Gross M. Virus outbreak crosses boundaries. Curr Biol. 2020;30(5): R191-R4.
2. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology. 2020; 5(4): 536-44.
3. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods in Molecular Biology. 2015; 1282: 1-23.
4. Tyrrell DAJ, Myint SH. Coronaviruses. In: th, Baron S, editors. Medical Microbiology. Galveston (TX)1996.
5. Lim YX, Ng YL, Tam JP, Liu DX. Human Coronaviruses: A Review of Virus-Host Interactions. Diseases. 2016; 4(3).
6. Nichols WG, Peck Campbell AJ, Boeckh M. Respiratory viruses other than influenza virus: impact and therapeutic advances. Clinical Microbiology Reviews. 2008; 21(2): 274-90.
7. van Woensel JB, van Aalderen WM, Kimpen JL. Viral lower respiratory tract infection in infants and young children. BMJ. 2003; 327(7405): 36-40.
8. Kolifarhood G, Aghaali M, Mozafar Saadati H, Taherpour N, Rahimi S, Izadi N, et al. Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. Archives of Academic Emergency Medicine. 2020; 8(1): e41.
9. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. Journal of Autoimmunity. 2020; 109: 102434.
10. Chase AJ, Semler BL. Viral subversion of host functions for picornavirus translation and RNA replication. Future Virology. 2012;7(2):179-91.
11. Nakagawa K, Lokugamage KG, Makino S. Viral and Cellular mRNA Translation in Coronavirus-Infected Cells. Advances in Virus Research. 2016; 96: 165-92.
12. Baez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Research. 2015; 115: 21-38.
13. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. 2020; 6(3): 315-31.
14. Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded proteinases and proteolytic processing in the Nidovirales. The Journal of General Virology. 2000; 81(Pt 4): 853-79.
15. Rimanshee A, Amit D, Vishal P, Mukesh K. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs 2020.
16. Arya A, Dwivedi VD. Synergistic effect of vitamin D and remdesivir can fight COVID-19. Journal of Biomolecular Structure and Dynamics. 2020: 1-2.
17. Hendaus MA. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. Journal of Biomolecular Structure and Dynamics. 2020: 1-6.
18. Kumar V, Dhanjal JK, Bhargava P, Kaul A, Wang J, Zhang H, et al. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. Journal of Biomolecular Structure and Dynamics. 2020: 1-13.
19. Kumar V, Jena M. Reverse vaccinology approach towards the in-silico multiepitope vaccine development against SARS-CoV-2. 2020.
20. Sindhu T, Akhilesh K, Jose A, Binsiya K, Thomas B, Wilson E. Antiviral screening of Clerodol derivatives as COV 2 main protease inhibitor in Novel Corona Virus Disease: In silico approaches. Asian Journal of Pharmacy and Technology. 2020; 10(2): 60-4.
21. Yadav AR, Mohite SK. A Novel Approach for Treatment of COVID-19 with Convalescent Plasma. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020; 12(3): 227-30.
22. Shankhdhar PK, Mishra P, Kannojia P, Joshi H. Turmeric: Plant Immunobooster against COVID-19. Research Journal of Pharmacognosy and Phytochemistry. 2020; 12(3): 174-7.
23. Farhana N, Ansari T, Ansari M. Sars-CoV-2leader-RNA-primed Transcription and RNA-Splicing prevention, control and Treatment. Asian Journal of Research in Chemistry. 2020; 13(4): 291-8.
24. Goswami S, Pal N, Singh RP, Singh A, Kumudhavalli M. A Meticulous Interpretation on a Sanguinary Disease COVID-19. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020; 12(3): 231-3.
25. Patil PA, Jain RS. Theoretical Study and treatment of Novel COVID-19. Research journal of Pharmacology and Pharmacodynamics. 2020; 12(2): 71-2.
26. Derouiche S. Current Review on Herbal Pharmaceutical improve immune responses against COVID-19 infection. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020; 12(3): 181-4.
27. Mor S, Saini P, Wangnoo SK, Bawa T. Worldwide spread of COVID-19 Pandemic and risk factors among Co-morbid conditions especially Diabetes Mellitus in India. Research Journal of Pharmacy and Technology. 2020; 13(5): 2530-2.
28. Jain MS, Barhate SD. Corona viruses are a family of viruses that range from the common cold to MERS corona virus: A Review. Asian Journal of Research in Pharmaceutical Sciences. 2020;10(3):204-10.
29. Naresh B. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian Journal of Pharmaceutical Research. 2020;10(3): 233-8.
30. Biovia DS. Discovery Studio Modeling Environment. 2020.
31. Sterling T, Irwin JJ. ZINC 15--Ligand Discovery for Everyone. Journal of Chemical Information and Modeling. 2015;55(11):2324-37.
32. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology. 2015; 1263: 243-50.
33. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry. 2010;31(2):455-61.
34. Kumar V, Dhanjal JK, Kaul SC, Wadhwa R, Sundar D. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (Mpro) of SARS-CoV-2 and inhibit its activity. Journal of Biomolecular Structure and Dynamics. 2020(just-accepted): 1-17.
35. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020:1-5.
36. Kandeel M, Al-Nazawi M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sciences. 2020:117627.
37. Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An Overview. Cold Spring Harbor Perspectives in Medicine. 2016;6(6).
38. Ramirez MS, Tolmasky ME. Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules. 2017;22(12).
39. Cartotto R. Topical antimicrobial agents for pediatric burns. Burns and Trauma. 2017; 5:33.
40. Dai T, Huang YY, Sharma SK, Hashmi JT, Kurup DB, Hamblin MR. Topical antimicrobials for burn wound infections. Recent Patents on Anti-infective Drug Discovery. 2010; 5(2): 124-51.
41. Kumar A, Naguib YW, Shi YC, Cui Z. A method to improve the efficacy of topical eflornithine hydrochloride cream. Drug Delivery. 2016; 23(5): 1495-501.
42. Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020:105949.
43. Trimipramine. Liver Tox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD)2012.
44. Rifkin A, Reardon G, Siris S, Karagji B, Kim YS, Hackstaff L, et al. Trimipramine in physical illness with depression. The Journal of Clinical Psychiatry. 1985; 46(2 Pt 2): 4-8.
45. Saef MA, Saadabadi A. Protriptyline. Stat Pearls. Treasure Island (FL) 2020.
46. Szalach LP, Lisowska KA, Cubala WJ. The Influence of Antidepressants on the Immune System. Archivum Immunologiae et Therapiae Experimentalis. 2019; 67(3): 143-51.
47. Cruz MP. Lenalidomide (Revlimid): A Thalidomide Analogue in Combination with Dexamethasone for the Treatment of All Patients with Multiple Myeloma. P and T: a peer-reviewed journal for Formulary Management. 2016; 41(5): 308-13.
48. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1): 22-32.